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Executive Summary
Polycystic ovarian syndrome (PCOS) is one of the most common endocrine disorders in
reproductive age women (Nikokavoura, Johnston, Broom, Wrieden, & Rolland, 2015). This
syndrome is often associated with systemic dysfunctions such as metabolic syndrome,
hypertension, and dyslipidemia. Common physical manifestations include: hirsutism, obesity,

acne, menstrual irregularities, and infertility (Kim et al., 2015). Other manifestations can include
alopecia, deep voice, and clitoromegaly (Patel, 2018). This multisystem disorder can also be
associated with depression, anxiety, and lower quality of life (Dokras et al., 2018).
Treatment often includes medications such as metformin and oral contraceptives (Patel,
2018). This condition is often treated with medications but with limited education about the
condition itself and its lifelong effects. Lifestyle interventions such as low calorie/low fat diet
and exercise are also considered part of the treatment plan for PCOS (Nikokavoura et al., 2015).
There is a lack of information and emphasis missing from the interactions between
providers and their patients with PCOS. This lack of information stimulated the change project
that focuses on education and emphasis on lifestyle interventions in patients with PCOS. This
paper proposes the Lifestyle Modification Change Project to help fulfill this lack of education
and emphasis on lifestyle modifications that occurs with patients diagnosed with PCOS. This
change project would include a 16-week lifestyle modification program that would evaluate preand post- participation data including: BMI, weight, inches, testosterone levels, menstrual cycle
regularity numbers, and quality of life questionnaire.
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The Lifestyle Modification Change Project addresses the need for change in addressing the

emphasis providers often fail to convey to PCOS patients. These lifestyle modifications provide
patients with a way to gain control over their diagnosis and increase their quality of life. The
following introduces the main objectives for the lifestyle modification benchmark change
project.
Lifestyle Modifications for PCOS
1.

Rationale for the Project

Polycystic ovarian syndrome affects an estimated 10% of reproductive age women (Domecq
et al., 2013). This syndrome is often attributed as the cause of 75% of cases of infertility
(Nikokavoura et al., 2015). Besides physical effects such as central obesity, hirsutism, acne,
alopecia, and seborrhea, PCOS can manifest as psychological effects such as depression, low
self-esteem, and reduced quality of life (Ramos et al., 2016).
Lifestyle interventions are often not emphasized enough by providers, not understood by
patients on how to complete lifestyle interventions, or not understood. PCOS patients are often
given medication with limited information on this syndrome. Patients often receive no education
on PCOS its life-long impact, or ways to improve its’ effect. This benchmark change project
addresses the lack of information, impact of lack of lifestyle interventions, and associated long
term effects of PCOS. Most providers recommend birth control medications with lifestyle
modifications (Dokras et al., 2018). However, health care providers need to emphasize and
thoroughly educate their patients on the benefits of lifestyle modifications. Patients often lack
the understanding of the impact of lifestyle interventions on their condition.
Women with PCOS are often frustrated with their diagnosis and treatment process (Dokras et
al., 2018). The lifestyle modification change project will educate providers and through them,
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PCOS patients on the benefits of lifestyle modifications in helping manage their PCOS. Through
education, exercise program and follow-up, PCOS patients will see the benefits of lifestyle
modifications and gain empowerment in their treatment process. At the end of the 16-week
lifestyle modification program, researchers expect to see positive results in BMI, weight, body
inches, menstrual regularity, testosterone levels, and quality of life.
2. Literature Synthesis.
Lifestyle modifications, which include diet and exercise, are part of first line treatment
recommendations for PCOS (Dokras et al., 2018). Several studies identify a weight loss as little
as 5% can have positive effects in patients with PCOS (Marzouk & Ahmed 2015). One specific
study completed by Marzouk and Ahmed (2015) explored the results of lifestyle modifications in
patients with PCOS. Their results consisted of improvements in menstrual function and body
inches (after using dietary modifications such as a high protein-low carbohydrate diet) (Marzouk
& Ahmed, 2015). The largest improvement was in menstrual cycles versus the control group.
These results demonstrate positive change after lifestyle modifications are implemented.
Another study by Zhang, Zheng, Guo, and Lai (2019) completed a meta-analysis of eight
randomized controlled trials that studies the effect of a low carbohydrate diet. Their study found
improvements in hormone levels, improved insulin resistance, and improved BMI after a low
carbohydrate diet was introduced. Also, to be mentioned is a study completed by Nikokavoura
et al. (2015) which explored lifestyle modifications using a low-calorie diet to help manage
PCOS. Their study found significant weight reduction and change in BMI after changes were
implemented (Nikokavoura et al., 2015). This evidence supports the intervention of diet into
lifestyle modifications to improve effects of PCOS.
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Exercise is another lifestyle intervention that is supported by evidence in treatment for
PCOS. A study completed by Ramos et al. (2016) explored the effect of resistance training on
quality of life in women with PCOS. Their study found significantly reduced testosterone levels,
social aspects, vitality, and mental health after implementing their intervention for 16 weeks. In
support of exercise, Costa et al. (2018) explored the effect aerobic training had on women with
PCOS. Their study included twenty-seven women with PCOS and compared them with a
control group. Costa et al. (2018) concluded that there is an improvement in cardiorespiratory
fitness, BMI, waist circumference, and mental health. Another study, a systematic review by
Pundir et al. (2019), explored the evidence found after non-pharmacological interventions, such
as exercise, were implemented. Improvements were found in fasting blood glucose levels, BMI,
and improved total testosterone levels (Pundir et al., 2019). This evidence suggests a significant
change after a lifestyle modification of exercise is completed.
A systematic review and meta-analysis was completed by Domecq et al. (2013) that studied
the effects of lifestyle modifications on patients with PCOS. Their study reviewed the results of
9 RCTs that included a total of 610 women. Diet, exercise, and a combination of both were
reviewed. Improvements found included: weight reduction and insulin resistance (glucose and
insulin levels) (Domecq et al., (2013). Haqq, McFarlane, Dieberg, and Smart (2015) also
explored the effect of lifestyle modifications through their systematic review and meta-analysis.
Their study of 12 articles found improvements in cardiorespiratory fitness and body composition
such as BMI and inches (Haqq et al., 2015). Similar results were found in a randomized
controlled study completed by Arentz et al. (2017). Their study found lifestyle modifications in
combination with medicine provided optimum improvement compared to medicine alone.
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Improvements were seen in BMI, hormones, insulin, and mental health after lifestyle
modifications were implemented (Arentz et al., 2017).

Another study of lifestyle interventions was completed by Fux Otta et al. (2010). Their study
was a randomized, double blind trial that found lifestyle interventions improved effects of PCOS
after interventions were implemented. Additionally, Legro et al. (2015) completed a randomized
controlled trial of lifestyle interventions and their impact on 149 women. At the end of their
study, improvements were found in weight, fertility, and metabolic health. Lastly, Naderpoor et
al. (2015) completed a systematic review and meta-analysis of 12 randomized controlled trials
that found optimum results with lifestyle modifications combined with medications versus
medications alone.
Clearly, evidence demonstrates the importance of lifestyle modification in the treatment of
PCOS. The Lifestyle Modification Change Project implements two modifications: diet and
exercise. These modifications are supported by strong research to support their effectiveness in
helping manage PCOS. Therefore, researchers anticipate positive results of the Lifestyle
Modification Change Project.
3. Project Stakeholders
Stakeholders for my change project include patients, healthcare providers, and the public as
there is a high population of women that are affected. Society is indirectly impacted by their
relationship to women who are affected. The public is indirectly affected by an individual’s
health care costs. Women are directly affected by PCOS. Health care providers are directly
affected in their care of their patients with PCOS. Sisters, mothers, wives, and daughters can all
be affected if they are of reproductive age. This disorder affects all aspects of women’s health.
PCOS can cause infertility, miscarriage, obesity, insulin resistance, hyperandrogenism, anxiety,
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and depression (Naderpoor et al., 2015). In other words, PCOS can affect physical health and
psychological health.
Patients and health care providers are the stakeholders in changing the emphasis on lifestyle
interventions as part of the treatment plan for PCOS. Because of the health impact of PCOS,
early and consistent intervention are necessary to decrease this disorder’s effect. Another way
that PCOS can negatively affect patients is decreased quality of life (Ding, Hardiman, Peterson,
& Baio, 2018). When quality of life is impacted negatively, this makes those directly affected
stakeholders. Additionally, healthcare providers and the public are stakeholders because of the
prevalence of PCOS in reproductive women and the healthcare costs associated with this
disorder.
In the change project, patients with PCOS would receive extra education that explains the
significance of lifestyle interventions in combination with medication treatment. They would
also receive education that PCOS is not cured after medication administration but is a lifelong
disorder that requires a lifestyle change. Thus, financial costs and health benefits would
improve. Therefore, the evidence supports the need for this change project and anticipates
positive results concerning stakeholder interests such as health benefits and financial cost.
4. Implementation Plan
This change project would focus on the implementation of lifestyle modifications in
combination with pharmacological interventions for best care of patients diagnosed with PCOS.
As this change project is a benchmark project, the implementation of the project is currently in
theory only. Starting with the education of providers, office staff, and patients, researchers will
educate all stakeholders. However, the most emphasis will be placed on the patient’s education.
The opportunity to participate in physical activity will also be given with primary care
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partnerships with area gyms and physical activity facilities with pre-approved activity programs.
A thorough evaluation of baseline data and comparison of data from post program participation
will be completed with the patient. By providing time for data evaluation between the patient
and the provider, this will allow for the patient to appreciate their efforts and the positive impact
their lifestyle modification has on their disorder. The result of the project will encourage patients
to continue their commitment to their lifestyle modifications. In other words, the success noted
after the interventions will empower the patient to take control of their diagnosis and will assist
in building a new outlook on life. The following paragraphs outline a step by step approach to
plan implementation.
First, education of staff and providers on the benefits of lifestyle interventions is the initial
step in completing a PCOS lifestyle intervention change program. These health care workers
must understand the impact of dietary and physical modifications on the disorder of PCOS.
Education will be completed in the form of verbal education and paper handouts. Education
regarding proper patient appointment times (20 mins +) will also be completed. Suggestions will
be made for these appointments to be scheduled at the end of the day. Appropriate follow up
will be completed by the researcher to answer any questions and for office staff to verbalize their
understanding of the benefits and program itself. This education time frame is estimated at 2
weeks for staff preparation for the program.
The next step is identification of patients newly diagnosed patients with PCOS or newly
referred patients with PCOS. Patients who are newly diagnosed with PCOS will be flagged by
the provider and office staff for potential candidates in the research project. Identification of
patients with PCOS will take place from August 2020 to the end of September 2020 for inclusion
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in the first rotation of the program. The expected time frame is immediately after identification
of diagnosis.
Thirdly, patients will be identified as candidates in the program. Criteria for participation
will be females aged 18-38 years old with a diagnosis of PCOS. The diagnosis of PCOS will be
completed by providers by the Rotterdam criteria for PCOS. Exclusion from participation will
be pre-existing conditions such as hypothyroidism, hyperthyroidism, cancer, cardiac history,
physical impairments for physical exercise, and recent surgery. The expected time frame is
within one week of identification.
An invitation to participate into the PCOS lifestyle modification program. Verbal and
written invitations and education will be given to patients during office visits from August 2020
to September 2020. Patient will be given invitation and education and encouraged to think about
participating in the program. Expected time frame is one week before follow up.
Next, informed consent will be obtained. Patients will have opportunity to ask questions and
sign written informed consent for the research project. Patients will take education information
home in the form of handouts away from the primary care office to limit perceived pressure to
participate. Decision to participate from initial invitation will be completed in one week. The
expected time frame is providers will schedule 20 mins for this office visit.
In the sixth step, baseline patient data will be obtained including lab work such as
testosterone levels, BMI, weight, measurements in inches, menstrual frequency (dates), and
quality of life questionnaire. Data will be gathered at follow up appointment after diagnosis of
PCOS or initial referral visit for PCOS. Data will be gathered during the second appointment.
Expected time frame is within one week of invitation which would include a 20-30 min for
patient office visit.
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Next, patients to participate in lifestyle interventions that include dietary recommendations

and physical activity programs. The researcher will partner with area gyms and exercise centers
for information of eligible exercise classes patients can participate in. Physical activity programs
and information will be given during second office visit during data collection. Patients to
participate in lifestyle modification recommendations for 16 weeks. During this visit, patients
will set up follow up office visit for new data collection. The time frame for this step is 16
weeks.
Lastly, a 16 week follow up will be completed at the end of the program. Patients will
present to the primary care office for data collection. Office visits for data collection will be
scheduled for 20-30 minutes with the provider. Providers will review new data post program
participation with data from pre- participation. Providers anticipate positive results in data that
include: decrease in BMI, decrease in weight, decreased measurements, decrease testosterone
levels, increased menstrual cycles, and improvement in quality of life questionnaire. Patients
will be given the option to continue in participation in the program for another 16 weeks for
another re-evaluation. Time frame for this step is 20-30 mins.
5. Timetable/Flowchart
The first step in preparation and implementation of the lifestyle modification change project
is education. This will take place in the first two weeks with preparation of providers and office
staff. The next time frame will extend from August 2020 to September 2020 in which eligible
patients with PCOS will be identified and invited to participate in the program. Patient will be
given information and education about the benefits of the program and involved lifestyle
modifications. They will have one week after invitation to decide to participate. During a 20minute office visit, patients will have opportunities to ask questions and complete informed
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consent as they will have taken home the contract and education prior to this visit. Within one
week of invitation to participate and after informed consent is completed, patients will complete
pre-participation data collection nurse visit. This will start the beginning of the 16-week
program start. After completion of the 16-week program, patients will complete a 20-minute
data collection visit and another meeting with the provider to review post participation results.
6. Data Collection Methods
When data is analyzed, the researcher anticipates a noted decrease from their preparticipation state numbers. Projected decreases are anticipated in BMI, weight (kg), inches, and
free testosterone levels. Projected increases are anticipated in menstrual regularity and increases
in health-related quality of life questionnaire scores. Success of the program is based on three
states: the patient continues to value the significance of lifestyle modifications, the provider
identifies with success of the program to encourage lifestyle modifications as a treatment plan,
and the patient health is positively influenced. Complete evaluation by the researcher will be
completed at the end of the 16-week program with a sit-down office visit between the
researcher/health care provider and the patient with PCOS. At the time of evaluation, data will
be presented that includes pre-participation number and post participation numbers. Numbers
will be a defining tool to evaluate the data concerning the program and both the researcher/health
care provider and the patient will benefit from the evaluation. Instructions for completing the
steps for evaluation and interpreting data are in the following paragraphs.
Firstly, the researcher will set up program conclusion appointments at the beginning of the
program with the patient. Appointments will be completed for data collection (nurse visit) at
completion of the program (16 weeks post) and for the conclusion interview (office visit) by the
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provider after the data is collected. This will allow for patient and provider planning as these
visits should be at the end of the clinic day.
After completion of the 16-week program, the patient will complete a nurse visit that will
include collection of data including: weight, BMI, body inches, menstrual cycles (counts),
testosterone level, and health questionnaire. Weight, BMI, and inches will be completed by the
nurse and measured in whole numbers. Menstrual cycles will be completed by having the patient
provide descriptions of the length and frequency of cycles since starting the program. The PCOS
health related quality of life questionnaire will be completed during the visit and the nurse will
complete the questionnaire evaluation tally. All data will be entered in the health care record for
easy access by the provider.
Next, after all participants have completed their data collection nurse visits, the provider will
complete data evaluation for the individual patient and the group. Group data will serve as a
comparison for the patient to rate their individual progress in relation to the group. This will be
completed by descriptive statistic techniques (see the following information on data collection)
During the final office visit between the provider and the patient at post completion of the
program the following will occur:
•

The provider will present individual data to the patient. The researcher anticipates
positive results since onset of the program.

•

The provider will compare the patient’s data with the groups data to allow for insight
on the patient’s success compared to the entire groups.

•

The provider will allow the patient to ask questions regarding their diagnosis and
disorder prognosis.

LIFESTYLE MODIFICATIONS
•

15

The provider will offer the patient an opportunity to re-enlist in the program again to
encourage commitment to lifestyle modification.

•

The office visit will be completed at the end of the office day to allow for more time
for the patient to ask questions and the provider to present a non-hurried approach for
the program completion.

Descriptive statistics will be used to evaluate the patient’s data as this is most appropriate to
display relationships between variables (Ali & Bhaskar, 2016). The PCOS lifestyle modification
program will yield individual variables for each patient. The numerical data will be obtained
from the office assessment. Pre-participation variables (A) will have post-participation variables
(B) subtracted from their original variable which will yield the new lifestyle modification change
(C). This formula will look like: “A - B=C.” This difference in variables will serve as the
patient’s individualized results. Group data will be completed using standard deviation. As this
is a benchmark project, no data has yet been collected to demonstrate correct values.
The population of the project would serve as Ó while X will be the resulted mean, i is the
element from the population, and N will be the number of my project population (Ali & Bhaskar,
2016). Mean will be found by the researcher by adding all the participants scores and dividing
the sum by the number of participants. The standard deviation will serve as the comparison for
the patient. This comparison will allow for the patient to appreciate their improvement or serve
as motivation as to what results are possible.
Evidence will be evaluated using descriptive statistics in the form of means and standard
deviation. Results will be compared from pre-participation data to post-participation data. Data
to be compared will be BMI, weight, inches, testosterone level, and quality of life questionnaire.
Positive results are anticipated after program participation. A follow up to discuss results and
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effects of participation will be scheduled as follow up office visits. For success of the program,
the researcher should see a decrease in BMI, inches, weight, testosterone level, and improved
quality of life. To monitor for success of the program, the researcher will evaluate patient group
data and post evaluation form regarding difficulty of modification adherence. The evaluation
form will include five questions with room for comments on suggestions. The researcher will
take all feedback into consideration into improving ongoing program enlistment.
7. Cost/Benefit Discussion
The Lifestyle Modification Change Project benefits include both financial and health.
Concerning financial concerns, there is little financial investment or cost. The researcher, on a
volunteer basis, will train providers and office staff over the two-week preparation period for an
estimated 5 hours. An estimate of costs for written education is $200.00 for copies, pens, and
paper for office training and patient education. Patient demographics and data will be flagged
through the health care office EMR system. There will be no cost to this process as all patients
identified with a PCOS diagnosis after training will be flagged through the computer EMR
system once settings are set. Time will not be wasted on identifying patients from previous
visits. Office visits will be scheduled as normal visits with patient covering their own visits as
normal.
Patients will also have options to complete physical activity recommendations by joining a
gym, recreational center, or completing physical activity at their own discretion. Patients will
have a choice as to how much money they want to spend on these choices. Education will be
incorporated into their visits, the difference being their visits will be scheduled at the end of the
clinic day to avoid pressure to the provider to finish sessions in a rushed manner. Data will be
analyzed in the providers EMR system. There is no cost as the EMR system will already be
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utilized. Limited costs are estimated as the only difference clinic visits will have extra scheduled
time for education at the end of the visit. This will be an opportunity to ask questions and the
patient should have received written education also.
PCOS is also associated with long term comorbidities such as coronary heart disease,
endometrial cancer, diabetes, and stroke (Ding et al., 2018). Since PCOS can have such
detrimental short and long term effects, effective early management is important. Research has
found that women with PCOS are twice as likely as women without this diagnosis to have
hospital admissions (Naderpoor et al., 2015). Although the health of patients is affected by
PCOS, financial burden can also be a factor. Ding et al. (2018) mention an estimated cost of
treatment for women with PCOS in the U.S. to be estimated at $4.36 billion per year. Ding et al.
(2018) also predict high comorbidities of PCOS and diabetes. 2.4% of PCOS patients had
completed a HBA1c test within the first year after diagnosis (Ding et al., 2018). These estimates
are just general estimates of the cost of PCOS. All stakeholders including society, health care
providers, and PCOS patients will avoid complications of PCOS and their associated financial
costs by supporting lifestyle modifications as part of PCOS treatment management.
8. Discussion of Results
The Lifestyle Modification Change Project is currently a benchmark project. There are no
official results. However, the researcher anticipates positive results as there is strong evidence
supporting the need for change. The evidence supports lifestyle modifications to help treat
PCOS. Change can be applied to the identified problem of lack of either education or emphasis
on the recommended treatment plan.
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9. Conclusions/Recommendations
Lifestyle modifications are first line treatment in combination for PCOS. The Lifestyle
Modification Change Project allows for patients to learn about lifestyle modifications and allows
them to be held accountable while learning to incorporate these modifications in everyday life.
The greatest strengths of this project are: the desire for patients to take control of their diagnosis
and the desire for providers to help their patients. Once patients see the benefits that are apparent
both physically and on paper, they will continue their lifestyle interventions. Providers want to
help their patients and will see positive results after emphasizing and educating their patients on
the benefits of lifestyle interventions in the treatment plan for PCOS. This project serves as a
jump start to changing their lifestyle to help manage their PCOS. As PCOS does not have a cure,
PCOS must be managed as a lifelong (reproductive life) condition. This researcher recommends
initiating the Lifestyle Modification Change Project in primary care offices for improved patient
outcomes.
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Strengths: randomized by computer,
good sample size.

Limitations: 3 mth follow up, future
possibly longer.
Non blinding, no placebo group.

Risks/harm: No serious adverse
events reported. Non serious adverse
effects minimal/less then
pharmaceutical (classic)
intervention.
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customized manufacturing of
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95% CI 0.2, 1.7,
P=0.012.
(Mental health)
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P=0.042.
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Strengths: randomized by computer,
good sample size.

Level 2: RCT

USPSTF: Level B, level of certainty
high.

Limitations: Small sample size,
initially randomized then not.
Generic questionnaire.
Non blinding, no placebo group.
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P= 0.04, I2= 72%

Strengths: comprehensive literature
research, tools to reduce error
measures, protocol driven research,
duplicate review.

LSM FBI: WMD
-2.1, 95% CI 3.3 TO -1.0, P < Limitations: High rates of loss of
followup. Short trial duration,
.001, I2=0%.
imprecision, heterogenity
LSM FGM:
WMD -0.8, 95%
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Non blinding, no placebo group.

Risks/harm: No serious adverse
events reported. Informed consent
obtained.

Feasibility: Worthwhile, lifestyle
modification can be implemented by
patients after education.

Level 2: meta-analsysis

USPSTF: Level B, level of certainty
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1.99)
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profile):
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level of certainty
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33

LIFESTYLE MODIFICATIONS
Legro
et al.,
2015,
Rando
mized
controll
ed trial
of
preconc
eption
interve
ntions
in
infertile
women
with
polycyc
stic
ovary
syndro
me

No
ne
stat
ed

Randomi
zed
controlle
d trial,
explored
preconce
ption
interventi
ons and
benefits
towards
PCOS

N=216,
n=149,
AT 12%
lifestyle,
8%OCP,
14%
combine
d,
reasons
listed on
Fig 1,
two-site
study,
women
age1840, BMI
2742kg/m2
,
Partipan
ts: OCP
(49),
LSI
(50),
Combin
ed (50)

IV= OCP,
LSM,
Combined
TX
DV= weights
(loss),
ovulation,
live births

HRQOL,
oral
glucose
tolerance
test.

M,
CI,
OR

Largest change:
(combined TX)
M -6.4%, 95%
CI, (-7.6- -5.2),
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HRQOL
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Strengths:
-randomized, equal 3 group
assignment, control group.
-good follow up, 6 mths post
delivery.
-TX interventions from proven
studies in obesity.

Limitation:
-no exploration in live births
between groups.
- small sample size

Risk/harm: steatorrhea/diarrhea,
breast pain, abd pain, dysmenorrhea,
AUB, HA

Feasibility: interventions easily
found, worthwhile to explore
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Menstrual
decrease
66.35±47.09
days(p=0.003)w/
met,
77.86±56.48
days
(p=0.009)w/plac
ebo. Sig decrease
testosterone 93.2
±22.02 to 76.36
±13.59ng/dl
(p=0.02) w/met,
Waist: 98.6
(84.1-113.1) to
93.7 (77.6109.8) p= 0.007,
insulin: 14.2 ±

Strengths: Randomized, doubleblind

Limitaitons: follow up only 4 mths,
no risk factors identified, small
sample size.

Risk/harm: none identified in article.

Feasibility:
-worthwhile, metformin easy to
obtain/prescribe, diet and exercise
also feasible.
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4.03 to 9.42 ±
5.13 , p = 0.003,
HOMA-IR 3.25
± 1.11 to 2.05 ±
1.36, p = 0.01,
BMI: 32.4 ± 6.7
to 31.53 ± 4.98,
p = 0.73

BW: 83.7 +/10.3 vs 90.1 +/12.4, BMI: 33.2
+/- 3.8 vs 35.7
+/- 4.6,
Hirsutism: 14.6
+/- 4.4 vs 18.2
+/- 6.2,
Menstrual epi:

Level 2 Hierarchy of evidence

USPSTF: Level B rating, Level of
Certainty: Moderate

Strengths: Randomized, doubleblind

Limitaitons: Small number of RCTs,
no risk factors identified, differences
in quality of publications
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in
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3.1 +/- 1.2 vs 2.3
+/- 1.3

Risk/harm: none identified in article.

Feasibility:
-worthwhile, consistent LCD has
significant impact on PCOS patients.

Level 2 Hierarchy of evidence

USPSTF: Level B rating, Level of
Certainty: Moderate
Not
stat
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in
the
arti
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Systemati
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and metaanalysis,
compare
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glucose

No
MD,
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s for
Cronbach’
s alpha.
QUICKI,
IFG, IGT,
OGTT

L+met. = lower
BMI MD -0.73
kg/m2, 95 % CI
(-1.14, -0.32),
p=0.0005,
adipose tissue
MD -92.49 cm 2,
95% CI (164.14, -20.84),
p=0.01,
Increased
menstrual cycles
MD 1.06, 95%

Strengths:
Thorough investigation of studies,
questioned authors when info not
present. Questions of inclusion
discussed/reviewed w/reviewers.
Used evidence synthesis expert.
Risk of bias assessment tool
assessed methodological qual.

Limitaitons:
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results in
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reported
attrition.
9 RCT
w/ LSI
+Met
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P, 4
RCT
Met
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W/L (±
P).
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(IFG/IGT)
DV IIanthropometr
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(body
composition)
,reproductive
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(hyperandrog
enism etc),
metabolic
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etc),
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CI (0.30, 1.82),
p=0.006, lower
test L +Met.:
MD -4.27 CI
95% (-11.83,
3.29), p= 0.27

Studies w/small sample size, high
attrition rates, poor adherence.

Feasibility:
Individualized, worthwhile tx.

Risk or harm: side effects of
metformin (N/V/D etc)

Level 1- Systemic reviews

USPSTF: Level B rating, Level of
certainty: Moderate
Nikoka
voura
et al.,
(2015).
Weight
loss for
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with
and
without
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ctive
analysis,
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low
calorie
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PCOS
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N=102,6
10.
Women
age 1875 yrs
with
BMI >
28 w/wo
PCOS.
Demogr

IV=VLCD
DV= (1)
weight loss,
(2) BMI, (3)
BP

No
M=+/ Weight loss
instrument - SD, (w/PCOS):
s for
P.
105.4+/- 18.9 kg
Cronbach’
vs 95.0 +/- 19.1
s alpha. T
kg, P< 0.001
test
(s/PCOS):
paired/unp
105.3+/-19.0kg
aired,
vs 94.9 +/- 19.5
Bonferron
kg, P < 0.001.
i post hoc
BMI (w/PCOS):

Strengths: analysis compared PCOS
and nonPCOS patients.
Retrospective analysis of data,
thorough investigation.

Limitaitons: DX of PCOS not same
criteria. Bias in financial status,
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very
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a
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facilitat
ors for
12
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pts.

Pundir Not
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w of
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Review
of
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(metaanalysis)

aphics
reported
compari
able. No
attrition
reported.

test for
variance.

38.9+/-6.4 kg/m
vs 35.0+/-6.6
kg/m, P< 0.001.
(s/PCOS): 38.8
+/-6.4kg/m vs
35.0 +/-6.8
kg/m, P <0.001.
BP (w/PCOS): 5.5+/- 6.1 mmHg
vs non PCOS 0.9+/- 1 mmHg,
P < 0.001.

costly commercial program. No
randomization. Ethnicity not
assessed.

Feasibility:
Individualized, worthwhile tx. for
low calorie diet. Behavior change
therapy difficult to initiate in PCP
office.

Risk or harm: no risks identified.

Level 3- retrospective analsys

USPSTF: Level B rating, Level of
certainty: Moderate
N= 273,
n = 12
systemat
ic
reivews.
Only

IV: diet,
physical
activity,
nutritional
supplements
(omega 3, n-

AMSTAR
tool and
GRADE
recom.
used

MD,
CI,
SMD,
OR,
pOR,
RR

Inositol on
Strengths: reviews with RCTs used.
menstration:
RR=6.8, 95% CI
2.8, 16.6.
Limitaitons: no risk factors
Lifestyle inter on identified, small sample size.
cycles: MD: -
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reviews
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tic
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syndro
me.

Ramos
et al.
(2016).
Quality
of life

reviews
with
RCTs
included
. No
languag
e
restrictio
n. No
date
restrictio
n

Not
stat
ed

Case
controlle
d study.
Impact of
restistanc

N=350,
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attrition
21 from
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acytlecystein
e, vit D,
inositol),
alternative
therapies
(herbal
medicine,
acupuncture.
DV:
endocrine
outcomes,
fertility
impact,
glycemic
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IV: RET,
DV:
(1)testostero
ne, (2)
androsternedi

1.19, 95% CI 2.35, -0.03.
testosterone
w/lifestyle:MD 1.64, 95% CI 2.94, -0.35.
lifestyle
intervention
w/BMI: MD 1.12, 95% CI 0.22,-0.03 (MD 0.15, 95% CI 0.24, -0.5).
Lifestyle
intervention
w/insulin: MD 2.02, 95%CI 3.28, -0.77,
WMD -2.1, 95%
CI -3.3, -1.0,
MD -1.10, 95%
CI -2.05, -0.16.

Linear
M+/transgressi SD,
ons model p,
used for
result

Test:88.93 +/34.73 vs 73.24
+/-24.63, OR
16.32, 95% 7.94,
24.71, p<0.01.

Risk/harm: none identified in article.

Feasibility:
-worthwhile interventions are
feasible.

Level 2 Hierarchy of evidence

USPSTF: Level B rating, Level of
Certainty: Moderate

Strengths: reviews with RCTs used.
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in
women
with
polycys
tic
ovary
syndro
me
after a
progra
m of
resistan
ce
exercis
e
training
.

e exercise cy and
on PCOS missed
pts.
apts.

one, (3)
compariso
BMI/waist
n, no
circ, (4) QOL model for
heterogen
eity.

OR,
CI

BMI= no
change. Waist
cir: 80.59 +/11.87 vs 79.35
+/- 10.54, OR=
0.84, 95% CI=
0.35 to 1.32,
p<0.01. QOL:
(functional cap)
86.86 +/- 13 vs
91.74 +/- 11.44,
OR= -4.86, 95%
CI= -8.89 to 0.84, p=0.02

Limitaitons: no risk factors
identified, small sample size, lack
of a control group.

Risk/harm: none identified in article.

Feasibility:
-worthwhile interventions are
feasible. Patients can engage in
resistance training as an
intervention.

Level 3 Hierarchy of evidence

USPSTF: Level B rating, Level of
Certainty: Moderate
Zhang,
X.,
Zheng,
Y.,
Guo,
Y., &
Lai, Z.
(2019).

No
ne
stat
ed

MetaAnalysis
on RCT.
Impact of
LCD on
PCOS

N=340,
n=8, no
attrition
mention
ed.

IV=LCD
DV(1)=BMI
DV (2)=
endorcrine

Heterogen
ity
measuresd
with tau2,
chi 2, I2.
No
specific

MD,
P, I2,
CI,
SMD

BMI= (SMD .04, 95% CI (1.38, -.070) P
<0.00001).
HOMA-IR=(
SMD -.66, 95%
CI (-1.01, -030)

Strengths: Randomized, doubleblind
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The
effect
of low
carbohy
drate
diet on
Ppolyc
ystic
ovary
syndro
me: A
MetaAnalysi
s of
Rando
mized
Control
led
Trials.

Articles
LCD on
attribut
es of
PCOS:
BMI, LH,
endocri
ne,
testoron
e.

hormones
DV (3)= LH

design
mentioned

DV (4)=
testosterone
DV (5)=
HOMA-IR

P = 0.0003).
Endocrine
Horm=
(P=0.95,I2=0%).
LH= p>0.05,
SMD 0.08, 95 %
CI (-0.48, 0.65).
testosterone=
(P<0.05,
I2=86%), SMD=1.01, 95% CI (2.08,
0.06)P>0.05)

Limitaitons: Small number of RCTs,
no risk factors identified, differences
in quality of publications

Risk/harm: none identified in article.

Feasibility:
-worthwhile, consistent LCD has
significant impact on PCOS patients.

Level 2 Hierarchy of evidence

USPSTF: Level B rating, Level of
Certainty: Moderate

Legend:
LSI=lifestyle intervention

HA=headache

P=p value

M=mean,

AUB=abnormal uterine bleeding

CI= confidence interval

SD= standard deviation

Abd=abdominal

I2= I2 statistic

FGM=Ferrimen-Gallaway score

LCD=low carb diet
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MD= mean difference

AT=attrition

DV=dependent variable

cardioresp=cardiorespiratory

OCP=oral contraceptive pills

IV=independent variable

Eval.= evaluate

TX=treatment

PCOS= polycystic ovary syndrome

RCTs= randomized controlled trials BW= body weight

LSM= lifestyle modification programs

met=metformin

HM=herbal medicaiton

D=diarrhea

L= lifestyle

N=nausea

V=vomiting

QOL=quality of life

WC= waiste circumference

LH= Leutinizing hormone

Comb= Combination tx

BMI=body mass index

P=placebo
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Appendix B
Lifestyle Modification Change Project Flowchart
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Appendix C
Health-Quality of Life Questionnaire
Please fill out the following questions and submit to health care provider:
1. Over the past year have you had problems with fertility or menstrual cycle regularity?
• Never
• Sometimes
• Often/Always
2. Over the past month have you felt unsexy?
• Never
• Sometimes
• Often/Always
3. Over the past month have you felt unhealthy?
• Never
• Sometimes
• Often/Always
4. Over the past 6 months have you had issues with body image?
• Never
• Sometimes
• Often/Always
5. Over the past 6 months have you felt frustrated with your diagnosis of PCOS?
• Never
• Sometimes
• Often/Always
6. Over the past 6 months have wanted to take control of your diagnosis of PCOS?
• Never
• Sometimes
• Often/Always
7. Over the past month have you had issues with facial hair growth?
• Never
• Sometimes
• Often/Always
8. Over the past month have you depression or anxiety?
• Never
• Sometimes
• Often/Always
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Appendix D
Evaluation Form
Please fill circle and answer the following questions:
1. The presentation of education material was adequate:
• Poor
• Good
• Excellent
2. The office staff and provider were able to answer questions:
• Poor
• Good
• Excellent
3. I was able to understand about the benefits of lifestyle interventions:
• Poor
• Good
• Excellent
4. I understand about the associated co-morbidities often found with PCOS:
• Poor
• Good
• Excellent
5. I am likely to complete lifestyle modifications after completing the program:
• Not likely
• Maybe
• Absolutely

Please leave comments, suggestions, or complaints for the researcher to evaluate:

LIFESTYLE MODIFICATIONS
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